Skip to main content
SpringerLink
Log in

Immunotherapy for Spondyloarthritis (SpA)

  • Chapter
  • First Online:
Therapeutic Vaccines as Novel Immunotherapy

  • 358 Accesses

Abstract

Spondyloarthritis (SpA) is an umbrella term for chronic inflammatory conditions that affect the joints and entheses (the region of attachment between ligaments or tendons and bones) at the sacroiliac region and spine, negatively impacting the patient’s daily life. Because human leukocyte antigen (HLA)-B27, a class I surface antigen encoded in the major histocompatibility complex (MHC), was identified as a strong genetic risk factor, several major theories for the pathological mechanisms have been proposed based on in vitro and translational studies. Additionally, emerging lines of evidence over the last decade suggest that the IL-23/IL-17 axis has a critical role (roles) in the pathology of SpA. Recently, molecular immunotherapy using antibodies has been studied and developed as a therapeutic option to treat SpA. This chapter describes antibody-based immunotherapies targeting arthritogenic inflammatory pathways based on proposed HLA-B27-related mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Allen RL, O’Callaghan CA, McMichael AJ, Bowness P (1999) Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol 162:5045–5048

    CAS  PubMed  Google Scholar 

  • Assier E, Bessis N, Zagury JF, Boissier MC (2017) IL-1 vaccination is suitable for treating inflammatory diseases. Front Pharmacol 8:6

    Article  PubMed  PubMed Central  Google Scholar 

  • Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705–1713

    Article  CAS  PubMed  Google Scholar 

  • Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS, Group MS (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373:2534–2548

    Article  CAS  PubMed  Google Scholar 

  • Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, Emery P (2005) The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology (Oxford) 44:1277–1281

    Article  CAS  Google Scholar 

  • Benjamin R, Parham P (1990) Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 11:137–142

    Article  CAS  PubMed  Google Scholar 

  • Benjamin RJ, Madrigal JA, Parham P (1991) Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 351:74–77

    Article  CAS  PubMed  Google Scholar 

  • Bird LA, Peh CA, Kollnberger S, Elliott T, McMichael AJ, Bowness P (2003) Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur J Immunol 33:748–759

    Article  CAS  PubMed  Google Scholar 

  • Bowness P (2002) HLA B27 in health and disease: a double-edged sword? Rheumatology (Oxford) 41:857–868

    Article  CAS  Google Scholar 

  • Bowness P, Ridley A, Shaw J, Chan AT, Wong-Baeza I, Fleming M, Cummings F, McMichael A, Kollnberger S (2011) Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 186:2672–2680

    Article  CAS  PubMed  Google Scholar 

  • Braun J, Sieper J (2004) Biological therapies in the spondyloarthritides – the current state. Rheumatology 43:1072–1084

    Article  CAS  PubMed  Google Scholar 

  • Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379–1390

    Article  PubMed  Google Scholar 

  • Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB, Group MS (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76:1070–1077

    Article  CAS  PubMed  Google Scholar 

  • Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD (1973) Ankylosing spondylitis and HL-A 27. Lancet 1:904–907

    Article  CAS  PubMed  Google Scholar 

  • Chan AT, Kollnberger SD, Wedderburn LR, Bowness P (2005) Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 52:3586–3595

    Article  CAS  PubMed  Google Scholar 

  • Colbert RA, DeLay ML, Klenk EI, Layh-Schmitt G (2010) From HLA-B27 to spondyloarthritis: a journey through the ER. Immunol Rev 233:181–202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA (2009) HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 60:2633–2643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dubash S, McGonagle D, Marzo-Ortega H (2018) New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. Ther Adv Chronic Dis 9:77–87

    Article  CAS  PubMed  Google Scholar 

  • Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S, Wordsworth T, Kenna TJ, Karaderi T, Thomas GP, Ward MM, Weisman MH, Farrar C, Bradbury LA, Danoy P, Inman RD, Maksymowych W, Gladman D, Rahman P, Spondyloarthritis Research Consortium of C, Morgan A, Marzo-Ortega H, Bowness P, Gaffney K, Gaston JS, Smith M, Bruges-Armas J, Couto AR, Sorrentino R, Paladini F, Ferreira MA, Xu H, Liu Y, Jiang L, Lopez-Larrea C, Diaz-Pena R, Lopez-Vazquez A, Zayats T, Band G, Bellenguez C, Blackburn H, Blackwell JM, Bramon E, Bumpstead SJ, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Freeman C, Gillman M, Gray E, Gwilliam R, Hammond N, Hunt SE, Jankowski J, Jayakumar A, Langford C, Liddle J, Markus HS, Mathew CG, OT MC, MI MC, Palmer CN, Peltonen L, Plomin R, Potter SC, Rautanen A, Ravindrarajah R, Ricketts M, Samani N, Sawcer SJ, Strange A, Trembath RC, Viswanathan AC, Waller M, Weston P, Whittaker P, Widaa S, Wood NW, McVean G, Reveille JD, Wordsworth BP, Brown MA, Donnelly P, Australo-Anglo-American Spondyloarthritis C, Wellcome Trust Case Control C (2011) Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43:761–767

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P, Group U-I-US (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375:1946–1960

    Article  CAS  PubMed  Google Scholar 

  • Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 14:585–600

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286–2291

    CAS  PubMed  Google Scholar 

  • Giles J, Shaw J, Piper C, Wong-Baeza I, McHugh K, Ridley A, Li D, Lenart I, Antoniou AN, DiGleria K, Kuroki K, Maenaka K, Bowness P, Kollnberger S (2012) HLA-B27 homodimers and free H chains are stronger ligands for leukocyte Ig-like receptor B2 than classical HLA class I. J Immunol 188:6184–6193

    Article  CAS  PubMed  Google Scholar 

  • Goodall JC, Wu C, Zhang Y, McNeill L, Ellis L, Saudek V, Gaston JS (2010) Endoplasmic reticulum stress-induced transcription factor, CHOP, is crucial for dendritic cell IL-23 expression. Proc Natl Acad Sci U S A 107:17698–17703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, Group U-S, Group U-S, Group U-S (2016) Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 375:345–356

    Article  CAS  PubMed  Google Scholar 

  • Gravallese EM, Schett G (2018) Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 14:631–640

    Article  CAS  PubMed  Google Scholar 

  • Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD (1990) Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 63:1099–1112

    Article  CAS  PubMed  Google Scholar 

  • Haroon N, Kim TH, Inman RD (2012) NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis 71:1593–1595

    Article  PubMed  Google Scholar 

  • Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B (1993) HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 342:646–650

    Article  CAS  PubMed  Google Scholar 

  • Inman RD (2006) Mechanisms of disease: infection and spondyloarthritis. Nat Clin Pract Rheumatol 2:163–169

    Article  PubMed  Google Scholar 

  • International Genetics of Ankylosing Spondylitis C, Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, Cremin K, Pryce K, Harris J, Lee S, Joo KB, Shim SC, Weisman M, Ward M, Zhou X, Garchon HJ, Chiocchia G, Nossent J, Lie BA, Forre O, Tuomilehto J, Laiho K, Jiang L, Liu Y, Wu X, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, Appleton L, Farrah C, Lau J, Kenna TJ, Haroon N, Ferreira MA, Yang J, Mulero J, Fernandez-Sueiro JL, Gonzalez-Gay MA, Lopez-Larrea C, Deloukas P, Donnelly P, Australo-Anglo-American Spondyloarthritis C, Groupe Francaise d’Etude Genetique des S, Nord-Trondelag Health S, Spondyloarthritis Research Consortium of C, Wellcome Trust Case Control C, Bowness P, Gafney K, Gaston H, Gladman DD, Rahman P, Maksymowych WP, Xu H, Crusius JB, van der Horst-Bruinsma IE, Chou CT, Valle-Onate R, Romero-Sanchez C, Hansen IM, Pimentel-Santos FM, Inman RD, Videm V, Martin J, Breban M, Reveille JD, Evans DM, Kim TH, Wordsworth BP, Brown MA (2013) Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 45:730–738

    Article  CAS  Google Scholar 

  • Jacques P, McGonagle D (2014) The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract Res Clin Rheumatol 28:703–710

    Article  PubMed  Google Scholar 

  • Kollnberger S, Bird L, Sun MY, Retiere C, Braud VM, McMichael A, Bowness P (2002) Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum 46:2972–2982

    Article  CAS  PubMed  Google Scholar 

  • Kollnberger S, Bird LA, Roddis M, Hacquard-Bouder C, Kubagawa H, Bodmer HC, Breban M, McMichael AJ, Bowness P (2004) HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol 173:1699–1710

    Article  CAS  PubMed  Google Scholar 

  • Lin P, Bach M, Asquith M, Lee AY, Akileswaran L, Stauffer P, Davin S, Pan Y, Cambronne ED, Dorris M, Debelius JW, Lauber CL, Ackermann G, Baeza YV, Gill T, Knight R, Colbert RA, Taurog JD, Van Gelder RN, Rosenbaum JT (2014) HLA-B27 and human beta2-microglobulin affect the gut microbiota of transgenic rats. PLoS One 9:e105684

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Mear JP, Schreiber KL, Munz C, Zhu X, Stevanovic S, Rammensee HG, Rowland-Jones SL, Colbert RA (1999) Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 163:6665–6670

    CAS  PubMed  Google Scholar 

  • Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD, Group S-PS (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76:79–87

    Article  CAS  PubMed  Google Scholar 

  • Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M, Group S-PS (2017) Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 389:2317–2327

    Article  CAS  PubMed  Google Scholar 

  • Powis SJ, Colbert RA (2016) Editorial: HLA-B27: the story continues to unfold. Arthritis Rheumatol 68:1057–1059

    PubMed  PubMed Central  Google Scholar 

  • Ramiro S, Landewe R, van Tubergen A, Boonen A, Stolwijk C, Dougados M, van den Bosch F, van der Heijde D (2015) Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open 1:e000153

    Article  PubMed  PubMed Central  Google Scholar 

  • Raychaudhuri SP, Raychaudhuri SK (2016) IL-23/IL-17 axis in spondyloarthritis-bench to bedside. Clin Rheumatol 35:1437–1441

    Article  PubMed  Google Scholar 

  • Schlosstein L, Terasaki PI, Bluestone R, Pearson CM (1973) High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 288:704–706

    Article  CAS  PubMed  Google Scholar 

  • Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, Laface DM, Cua DJ (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18:1069–1076

    Article  CAS  PubMed  Google Scholar 

  • Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73:95–100

    Article  CAS  PubMed  Google Scholar 

  • Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, Fiore S, Momtahen T, Yancopoulos GD, Stahl N, Inman RD (2015) Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 74:1051–1057

    Article  CAS  PubMed  Google Scholar 

  • Smith JA, Colbert RA (2014) Review: the interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol 66:231–241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62:1290–1297

    Article  CAS  PubMed  Google Scholar 

  • Turner MJ, Delay ML, Bai S, Klenk E, Colbert RA (2007) HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum 56:215–223

    Article  PubMed  Google Scholar 

  • Van Praet L, Van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, Glorieus E, Peeters H, Mielants H, De Vos M, Cuvelier C, Elewaut D (2013) Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 72:414–417

    Article  PubMed  Google Scholar 

  • Wendling D (2013) Looking for the best target for biologic treatment of spondyloarthritis. Expert Rev Clin Immunol 9:1005–1007

    Article  CAS  PubMed  Google Scholar 

  • Wendling D, Toussirot E (2004) Anti-TNF-alpha therapy in ankylosing spondylitis. Expert Opin Pharmacother 5:1497–1507

    Article  CAS  PubMed  Google Scholar 

  • Wong-Baeza I, Ridley A, Shaw J, Hatano H, Rysnik O, McHugh K, Piper C, Brackenbridge S, Fernandes R, Chan A, Bowness P, Kollnberger S (2013) KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis. J Immunol 190:3216–3224

    Article  CAS  PubMed  Google Scholar 

  • Zochling J, Smith EU (2010) Seronegative spondyloarthritis. Best Pract Res Clin Rheumatol 24:747–756

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Health Development and Medicine, School of Medicine, Osaka University, Suita, Osaka, Japan

    Jiao Sun & Hiroki Hayashi

Authors
  1. Jiao Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroki Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroki Hayashi .

Editor information

Editors and Affiliations

  1. Department of Health Development and Medicine, Osaka University, Graduate School of Medicine, Suita, Osaka, Japan

    Hironori Nakagami

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sun, J., Hayashi, H. (2019). Immunotherapy for Spondyloarthritis (SpA). In: Nakagami, H. (eds) Therapeutic Vaccines as Novel Immunotherapy. Springer, Singapore. https://doi.org/10.1007/978-981-32-9628-2_5

Download citation

Publish with us

Policies and ethics

Search

Navigation